SS Innovations International Inc. develops and commercializes surgical robotic technologies centered on the SSi Mantra Surgical Robotic System, a modular multi-arm platform used across multiple surgical specialties. Company news commonly covers SSi Mantra procedure milestones, global system installations, telesurgery demonstrations, regulatory approvals in international markets, and financial results tied to installations, procedures and revenue.
Updates also address the company’s surgical robotics ecosystem, including the SSi MantrAsana tele-surgeon console, the MantraM mobile robotic telesurgery unit, SSi Mudra instrumentation, and development-stage concepts such as SSi Vimana Aero, SSi Avtara and SSi Operion. Capital actions, Nasdaq trading status and company-hosted robotic surgery conferences are additional recurring themes.
SS Innovations (OTC: SSII) announced the engagement of BDO India LLP as its new auditor. This move aims to facilitate the uplisting of SSII’s common stock to a National Securities Exchange and reinforce transparent financial practices. The company has reported significant operational success with 32 installations of its SSi Mantra Surgical Robotic System in India, contributing to four new cardiac surgery programs. For Q1 2024, SS Innovations sold 8 SSi Mantra systems, generating revenues of approximately $7 million, surpassing the total revenue for 2023. CEO Dr. Sudhir Srivastava emphasized the commitment to transparent practices and global expansion, while COO Barry Cohen highlighted the strategic importance of BDO's engagement in supporting long-term growth and market positioning.
SS Innovations has announced that its SSi Mantra Surgical Robotic System has been used to perform over 100 robotic cardiac surgeries, signaling significant market expansion. The SSi Mantra, featuring a unique fifth arm capability, has been utilized in more than 1000 procedures globally. The company anticipates FDA and CE Mark approvals by early 2025, further enhancing its market position. The global cardiac surgery device market is projected to grow from $17.1 billion in 2023 to $24.9 billion by 2030, while the surgical robotics market is expected to increase from $78.8 billion in 2022 to $188.8 billion by 2032. SS Innovations, through its comprehensive robotic cardiac surgery program, aims to provide less invasive, lower cost, and superior outcomes for patients worldwide.
SS Innovations International, Inc. (SSII) achieved a significant milestone by successfully performing the first infant pyeloplasty using its flagship SSi Mantra Surgical Robotic System. The procedure, led by Dr. Chandra Mohan Vaddi in Hyderabad, India, was a success on a 12-month-old baby. The SSi Mantra is the first surgical system made in India and is cost-effective with regulatory approval in India, Guatemala, and Indonesia. The system has been used in over 1000 surgical procedures across various specialties. SS Innovations is seeking regulatory approval in the US and EU by late 2024 or 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.